Uniphar | Clinical merges with BMclinical

Feb 18, 2026 | News

Image Source: Bringing global capabilities together: Uniphar | Clinical’s facilities in Europe and the U.S. now operate as one unified clinical supply platform, strengthening end-to-end support for sponsors worldwide.
Written by: Contributor
On behalf of: Life Science Daily News

Leading global healthcare services provider Uniphar announces a strategic merger between Uniphar | Clinical and BMclinical, reinforcing Uniphar | Clinical’s integrated clinical supply offering and solidifying its position as a trusted partner to pharmaceutical and biotech companies worldwide.  

As part of Uniphar’s global platform supporting the full product lifecycle – from early clinical development through to commercialization and beyond – Uniphar | Clinical leverages scalable infrastructure and deep expertise to provide bespoke packaging, labeling, storage and distribution solutions, while BMclinical brings extensive experience in comparator sourcing and clinical trial supply.  

The combined Uniphar | Clinical offering will streamline clinical supply chains, minimize execution risk, and ensure continuity from study initiation through to completion, helping sponsors deliver therapies to patients faster. In addition, this broader offering enhances Uniphar’s ability to support partners across every stage of development, capitalizing on the scale and efficiency of a unified global sourcing model.  

“As global trials become more complex, sponsors increasingly value partners who can combine scale with specialist expertise,” said Dermot Ryan, Chief Operating Officer at Uniphar.
“By aligning BMclinical’s sourcing capabilities with Uniphar | Clinical’s integrated platform, we provide a comprehensive suite of clinical services based on agility and dependability that set a new standard for our partners and ultimately accelerate patient access to critical therapies.” 
 

Integrated services   

Building on Uniphar | Clinical’s and BMclinical’s combined expertise, the new partnership offers a comprehensive range of integrated services designed to support every stage of clinical trial supply, including: commercial drug supply capability including global sourcing of comparators; packaging and labeling services spanning both primary and secondary clinical packaging; global storage and distribution capabilities, including compliant facilities equipped with real-time temperature monitoring; and overage management solutions.   

With strategically located GMP- and GDP-compliant flagship facilities in Lelystad, the Netherlands, and Raleigh, North Carolina, alongside a distribution footprint spanning Europe, North America, APAC, and MENA, the partnership is positioned to deliver temperature-sensitive clinical materials reliably, wherever trials are underway.  

Shanelle Austin-Mehta, Director of Uniphar | Clinical said: 

“Bringing the expertise of Uniphar | Clinical and BMclinical together creates an unparalleled service offering to the pharmaceutical and biotech industry – one designed to anticipate challenges and provide the reliability sponsors need to keep studies on track.”  

For more information, visit https://unipharclinical.com/   

    References: None.

    Articles that may be of interest

    Weekly News Roundup | 2 November 2026

    Weekly News Roundup | 2 November 2026

    Life science news 2 November 2026: four approvals, three deals and a UK Budget investment package. Ferring has agreed to acquire Gameto in a deal worth up to $1.3825bn. The FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis. The MHRA...

    read more
    Eppendorf and BioLabs Expand Collaboration to Munich

    Eppendorf and BioLabs Expand Collaboration to Munich

    The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies. It builds on existing partnerships at BioLabs sites across the US, Germany and France. HAMBURG and MUNICH, Germany, 21 October 2026...

    read more
    Weekly News Roundup | 26 October 2026

    Weekly News Roundup | 26 October 2026

    Life science news 26 October 2026: two major deals, three US approvals, two UK updates and a reverse merger. Roche signed an antibody-drug conjugate deal with Hansoh. Merck KGaA agreed to buy Silence Therapeutics for about $1.3bn. The FDA granted accelerated approval...

    read more

    Articles that may be of interest

    Weekly News Roundup | 2 November 2026

    Weekly News Roundup | 2 November 2026

    Life science news 2 November 2026: four approvals, three deals and a UK Budget investment package. Ferring has agreed to acquire Gameto in a deal worth up to $1.3825bn. The FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis. The MHRA...

    read more
    Eppendorf and BioLabs Expand Collaboration to Munich

    Eppendorf and BioLabs Expand Collaboration to Munich

    The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies. It builds on existing partnerships at BioLabs sites across the US, Germany and France. HAMBURG and MUNICH, Germany, 21 October 2026...

    read more
    Weekly News Roundup | 26 October 2026

    Weekly News Roundup | 26 October 2026

    Life science news 26 October 2026: two major deals, three US approvals, two UK updates and a reverse merger. Roche signed an antibody-drug conjugate deal with Hansoh. Merck KGaA agreed to buy Silence Therapeutics for about $1.3bn. The FDA granted accelerated approval...

    read more